Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets

  • Weyandt J
  • Thompson C
  • Giaccia A
  • et al.
N/ACitations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy treatments for obsessive-compulsive disorder (OCD). Clomipramine-is effective in OCD but associated with more adverse events. Typically, higher doses of antidepressants are required for OCD. Up to 50% of patients do not respond to initial treatment of OCD. Treatment options for nonresponders include augmentation of antidepressants with atypical antipsychotics, among other strategies. First-line treatments for anxiety disorders include SSRIs, serotonin norepinephrine reuptake inhibitors, and pregabalin. Tricyclic antidepressants are equally effective as SSRIs, but are less well tolerated. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of dependency and tolerance. Other treatment options include irreversible and reversible monoamine oxidase inhibitors, the atypical antipsychotic quetiapine, and other medications. Cognitive-behavioral therapy has been sufficiently investigated in controlled studies of OCD and anxiety disorders and is recommended alone or in combination with the above medications.

Cite

CITATION STYLE

APA

Weyandt, J. D., Thompson, C. B., Giaccia, A. J., & Rathmell, W. K. (2017). Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. American Society of Clinical Oncology Educational Book, 37, 825–832. https://doi.org/10.14694/edbk_175561

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free